Fig. 4: In situ retention and O2 self-supply of IL/aC@RBAH.
From: In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy
a Photographs showing the in vivo degradation behavior of subcutaneous IL/aC@RBAH on different days. b, c Whole-animal in vivo fluorescence imaging (b) and corresponding fluorescence quantification (c) of orthotopic 4T1 tumor-bearing mice after intratumoral injection of IL-Cp&aC, IL-Cp/aC@RBC, and IL-Cp/aC@RBAH. d Concentrations of aCTLA-4 in serum of 4T1 tumor-bearing mice after intratumoral injection of saline, aCTLA-4, and IL/aC@RBAH. e Concentrations of IL-12 in serum of 4T1 tumor-bearing mice after intratumoral injection of saline, IL-12, and IL/aC@RBAH. f–i Detection of liver function indexes including ALT (f) and AST (g), and kidney function indexes, including BUN (h) and CREA (i) in 4T1 tumor-bearing mice after intratumoral injection of saline, IL&aC, RBAH, and IL/aC@RBAH. The normal range of liver function and kidney function indexes was marked by dash lines. j Representative PA images and corresponding quantification of sO2 levels in 4T1 tumors before and after injection of IL/aC@RBC and IL/aC@RB. k Representative PA images and corresponding quantification of sO2 levels in 4T1 tumors at different time points after injection of IL/aC@RB and IL/aC@RBAH. l Representative CLSM images of immunostaining (HIF-1α, CD31) in 4T1 tumors after different treatments. Green, HIF-1α; red, CD31; blue, DAPI. Scale bar, 100 μm. m Representative γ-H2Aχ fluorescence staining images of 4T1 tumors after different treatments. Green, γ-H2Aχ; blue, DAPI. Scale bar, 200 μm. Experiments in (a, j, k, l, m) were independently repeated three times with comparable results. Data in (c–k) were presented as mean ± SD. n = 3 mice per group. Statistical significance was determined using two-way ANOVA (c) and two-sided unpaired student’s t-test (d, e, g, j, k). Source data are provided as a Source Data file.
